Literature DB >> 1333776

The Second International Standard for anti-poliovirus sera types 1, 2 and 3.

D J Wood1, A B Heath.   

Abstract

The Second International Standard for anti-poliovirus sera types 1, 2 and 3 was established by the WHO Expert Committee on Biological Standardization in 1991 on the basis of an extensive collaborative study. Nine laboratories from eight countries participated and all used neutralizing antibody assays. The standard is a human serum pool which contains antibodies to all three poliovirus types and replaces the three previously established monovalent standards which were all hyperimmune monkey sera. The standard was assigned an activity of 25 IU of anti-poliovirus serum (type 1) human: 50 IU of anti-poliovirus serum (type 2) human; and 5 IU of anti-poliovirus serum (type 3) human. The study also showed significant interlaboratory differences in relative potency are observed when human sera are compared to hyperimmune monkey sera. It was therefore recommended that National laboratory references are established from human sera.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1333776     DOI: 10.1016/s1045-1056(05)80039-9

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  5 in total

1.  Immunogenicity of oral poliovirus vaccine administered in mass campaigns versus routine immunization programmes.

Authors:  G Richardson; R W Linkins; M A Eames; D J Wood; P J Campbell; E Ankers; M Deniel; A Kabbaj; D I Magrath; P D Minor
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

2.  Enzyme-linked immunosorbent assay-based inhibition test for neutralizing antibodies to polioviruses as an alternative to the neutralization test in tissue culture.

Authors:  G Edevåg; B Wahren; A D Osterhaus; V A Sundqvist; M Granström
Journal:  J Clin Microbiol       Date:  1995-11       Impact factor: 5.948

3.  Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines.

Authors: 
Journal:  Bull World Health Organ       Date:  1996       Impact factor: 9.408

4.  Immunity status of adults and children against poliomyelitis virus type 1 strains CHAT and Sabin (LSc-2ab) in Germany.

Authors:  Maren Eggers; Elena Terletskaia-Ladwig; Holger F Rabenau; Hans W Doerr; Sabine Diedrich; Gisela Enders; Martin Enders
Journal:  BMC Infect Dis       Date:  2010-12-09       Impact factor: 3.090

5.  Immunity status against poliomyelitis in Germany: determination of cut-off values in International Units.

Authors:  Sabine Diedrich; Hermann Claus; Eckart Schreier
Journal:  BMC Infect Dis       Date:  2002-02-06       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.